New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes.
- Author:
Won Young LEE
1
Author Information
- Publication Type:Review
- Keywords: Glucagon-like peptide-1 receptor; Diabetes mellitus; Insulin; Glucagon
- MeSH: Awards and Prizes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1*; Glucagon-Like Peptide-1 Receptor; Hepatocytes*; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity
- From:Endocrinology and Metabolism 2017;32(1):1-5
- CountryRepublic of Korea
- Language:English
- Abstract: It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors, obesity and lipotoxicity can increase the risk of T2DM. Glucagon-like peptide 1 (GLP-1) receptor agonists are novel antidiabetic drugs with multiple effects. They can stimulate glucose-dependent insulin secretion, inhibit postprandial glucagon release, delay gastric emptying, and induce pancreatic β-cell proliferation. They can also reduce the weight of patients with T2DM and relieve lipotoxicity at the cellular level. Many intracellular targets of GLP-1 have been found, but more remain to be identified. Elucidating these targets could be a basis for developing new potential drugs. My colleagues and I have investigated new targets of GLP-1, with a particular focus on pancreatic β-cell lines and hepatic cell lines. Herein, I summarize the recent work from my laboratory, with profound gratitude for receiving the prestigious 2016 Namgok Award.
